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Introduction 
Crohn’s disease is a chronic inflam-
matory disorder which is distinct from other 
inflammatory bowel conditions, such as 
ulcerative colitis, in its ability to involve the 
GI tract anywhere from mouth to perianal 
area.
1
 It was long thought as a disease 
limited to the gastrointestinal tract usually 
presenting with chronic diarrhea, abdominal 
pain, weight loss, rectal bleeding, and fever. 
Intestinal complications include obstruction, 
fistulas, abscesses, toxic megacolon, mal-
absorption, and colorectal cancers. Other 
extra-intestinal modes of presentation, such 
as upper respiratory tract involvement, 
retinal detachment, arthritis, hepatobiliary 
involvement, erythema nodosum, pyoderma 
gangrenosum, spondylitis, and delayed 
growth, sometimes are the key to binding 
multi-system-associated symptoms into the 
diagnosis of Crohn’s disease.2 These may 
sometimes pre-date bowel symptoms by 
several weeks or even years or develop 
during the course of active bowel disease. 
Presentation with extra-intestinal symptoms 
may result in delayed or missed diagnosis.  
Pyoderma gangrenosum is a rare 
neutrophilic noninfectious dermatosis. 
Etiology remains unclear, however, inflam-
matory bowel disease is the most common 
underlying disorder associated with it. The 
presence of pyoderma gangrenosum usually 
is a predictor of severity of gastrointestinal 
disease even without apparent manifest-
ations.
3
  
Case Report 
A 52-year-old male with Crohn’s disease 
presented with multiple bilateral leg ulcers 
below the knee (Figure 1). His Crohn’s 
disease was diagnosed 15 years prior and he 
was taking sulfasalazine. He presented with 
bleeding from right leg ulcers and bilateral 
moderate to severe pain. He had episodes of 
diarrhea seven days before presentation with 
watery stools 3-4 times daily, which 
resolved on its own. He had chronic soft 
stools and not had formed bowel movement 
for many years. He denied any blood in his 
stools. He complained of decreased appetite 
and episodes of intermittent nausea but no 
vomiting. 
On examination, the patient was afebrile 
and tachycardic with mildly elevated blood 
pressure. The oropharynx was free of ulcers 
and erosions. Abdominal examination 
revealed an obese, nontender abdomen with 
bowel sounds. Rectal examination was 
negative for any ulcers or bleeding. The 
lower extremities were characterized by 
multiple, irregular, purulent bleeding ulcers 
below the knee covering both legs 
circumferentially. 
The laboratory evaluation was signifi-
cant for leukocytosis with 23% bands. The 
fecal occult blood test was positive for 
blood. His C-reactive protein and 
erythrocyte sedimentation rate (ESR) were 
elevated. Hepatitis serologies and blood 
cultures were negative. Wound cultures 
were positive for staphylococcus aureus and 
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Figure1. Bilateral pyoderma gangrenosum ulcers with circumferential involvement in both legs.  
pseudomonas. The Crohn’s Disease Activity 
Index (CDAI) was 232, indicative of disease 
activity to be in moderate to severe range. 
In light of the leukocytosis, the patient 
was started on intravenous vancomycin and 
piperacillin/tazobactam along with debride-
ment of wounds with daily dressing 
changes. Colonoscopy revealed mucosal 
changes with ulceration and severe con-
gestion as well as pseudopolyp formation 
within the mid to distal transverse colon, 
ascending colon, and cecum. The terminal 
ileum was spared. Biopsies showed evidence 
of chronic active inflammation, focal acute 
cryptitis, crypt abscess, aphthous ulcers, and 
basal lymphoid aggregate with no evidence 
of dysplasia or granuloma. Rectum and 
terminal ileum generally were spared. 
The patient was switched to cephalexin, 
ciprofloxacin, and prednisone after 
completion of seven days of intravenous 
antibiotics. His leg ulcers improved with 
prednisone and he was to be started on 
infliximab after the bacterial infection was 
resolved. QuantiFERON® testing for latent 
tuberculosis was indeterminate twice and he 
was started on antituberculous therapy 
before infliximab could be initiated. 
However, his leg ulcers healed and follow-
up laboratory evaluation reflected this 
clinical improvement as evidenced by 
improvement in anemia, leucocytosis, and 
erythrocyte sedimentation rate. 
 
Discussion 
Crohn’s disease is part of the group of 
inflammatory bowel diseases associated 
with the NOD2 gene contributing to an 
inappropriate hyperactive response to 
intestinal microbes.
4
 The disease course has 
relapsing and remitting episodes of multiple 
gastrointestinal manifestations from oro-
pharynx to anus, with the ileum and colon 
more commonly involved. Crohn’s disease 
is associated with multiple systemic 
symptoms such as arthritis, anemia, 
malnutrition, and skin manifestations like 
pyoderma gangrenosum.  
First described in 1930, pyoderma 
gangrenosum is a non-infectious neutro-
philic dermatosis.
5
 The condition has an 
idiopathic form as well as one associated 
with an underlying disease such as inflam-
matory bowel disease, arthritis, hemato-
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logical disease, human immunodeficiency 
syndromes, and solid tumors.
5,6
 Pyoderma 
gangrenosum is associated with ulcerative 
colitis, but is rare in Crohn's disease. Pyo-
derma gangrenosum adds 20 points to the 
CDAI which includes signs and symptoms, 
such as the number of bowel movements, 
abdominal pain, and anemia, and 
complications, such as arthritis, anal fissure, 
uveitis, and pyoderma gangrenosum. 
Erythema nodosum, on the other hand, 
occurs more commonly in Crohn's disease.
6
 
Pyoderma gangrenosum usually begins with 
fluctuant nodules and an inflammatory halo 
which expands peripherally to form an ulcer. 
The ulcer may progress with irregular or 
sharply circumscribed violaceous raised 
edges to any of the four prototypic forms: 
ulcerative, pustular, bullous, or vegetative. 
The lower extremities and the trunk are most 
affected sites.
7
 Each form may develop into 
another type or become ulcerative.
8
 The 
diagnosis does not depend on histological 
biopsy and a clinical-histological approach 
is required to make the diagnosis and to 
exclude other ulcerative processes.
9
  
The first line of treatment for pyoderma 
gangrenosum is the use of systemic 
corticosteroids like methylprednisolone, 
together with treatment of any underlying 
cause.
10
 Many therapeutic approaches like 
cyclosporine, mycophenolate mofetil, azath-
ioprine, and tumor necrosis factor-alpha 
(TNF-alpha) inhibitors are used, however, 
they have inconsistent results. A common 
problem is repeated flare-ups in patients 
with Crohn’s disease who become resistant 
to once stable therapy or become refractory 
to first line agents (e.g., glucocorticoids, 5-
ASAs, and antibiotics). They have relapsing 
events, such as pyoderma gangrenosum, 
with repeated episodes of gastrointestinal 
symptoms.
11
 Treatment options like inflix-
imab, azathioprine, and 6-mercaptopurine 
show increased efficacy, with maintenance 
of remission, and improvement in quality of 
life in moderate to severe Crohn’s disease 
refractory to conventional treatment.
12
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